HKEX Chapter 18A and 18C Listings

What Chapter 18A and 18C listings offer

Chapter 18A and 18C listings let companies that cannot meet Hong Kong's ordinary profit or revenue tests join the Main Board of the Stock Exchange of Hong Kong. Chapter 18A, introduced in 2018, is for pre-revenue or early-revenue biotech companies. Chapter 18C, in force since 31 March 2023, is for specialist technology companies in five defined industries. Both replace financial track-record tests with minimum market capitalisation, a research and development history, and validation by sophisticated investors, and both add disclosure and investor protection features.

For Mainland technology and life sciences companies these chapters are often the most realistic offshore listing route. They sit alongside the domestic alternatives on the STAR Market, ChiNext and the Beijing Stock Exchange, and many boards compare the two before committing.

This page sets out the eligibility tests, the temporary Chapter 18C thresholds that run to 31 August 2027, the Technology Enterprises Channel launched in 2025, a step-by-step timetable, the Mainland and cross-border issues applicants should expect, and the obligations that continue after listing. It is general information only; detailed requirements are in the Listing Rules and the Exchange's guidance.

Chapter 18A biotech listings

Chapter 18A applicants must be primarily engaged in research and development of a core biotech product, such as a pharmaceutical, a biologic or a medical device. The Exchange expects the applicant to show that its science, not merely its funding, is real. Key expectations include:

• an expected market capitalisation at listing of at least HK$1.5 billion;
• at least one core product that has passed the concept stage, which for a pharmaceutical typically means completion of Phase I clinical trials with no objection from the relevant regulator to begin Phase II or later trials;
• operation in its current line of business for at least two financial years before listing, under substantially the same management;
• meaningful investment from sophisticated investors well before the IPO; and
• working capital sufficient to cover at least 125% of its costs, largely R&D and administrative costs, for at least the next 12 months.

Shares of Chapter 18A companies carry a "B" stock marker until the company meets an ordinary financial eligibility test. The Exchange closely examines any change of business that would take a company away from its biotech focus, and material changes need its consent. Licensing income and partnering deals, discussed under biotech licensing and business development, often shape both valuation and the Exchange's view of the core product.

Core product and pipeline disclosure

Much of the Exchange's review of a Chapter 18A applicant focuses on the core product: its regulatory status in each market, the data supporting each claimed milestone, licensing rights and royalty obligations, and the risks of failure. The prospectus must describe clinical progress accurately and avoid language that overstates efficacy. Where the core product is in-licensed, the Exchange will look at the scope and duration of the licence and whether the applicant has done enough of its own R&D to own the story. Applicants with multiple products should be clear which one is core and why.

Chapter 18C specialist technology listings

Chapter 18C covers five specialist technology industries: next-generation information technology, advanced hardware and software, advanced materials, new energy and environmental protection, and new food and agriculture technologies. Acceptable sectors are listed in the Exchange's Guide for New Listing Applicants. Companies outside them may still apply if they can show the required attributes, after a confidential pre-IPO enquiry. The chapter distinguishes commercialised companies, which have reached a revenue threshold from their specialist technology business, from pre-commercial companies, which have not.

The temporary reductions were announced by the SFC and HKEX on 23 August 2024 and are described in the HKEX announcement. The reduced thresholds apply to applicants whose expected listing date is on or after 1 September 2024 and whose applications, including renewals, are submitted on or before 31 August 2027. Applicants that may not file by then should plan for the possibility that the original thresholds return.

Sophisticated investor validation in practice

Investor validation is where many Chapter 18A and 18C listings succeed or stall. The Exchange wants evidence that informed, independent professionals have priced the business with their own money well before the IPO. That usually means specialist funds, strategic corporates with relevant expertise, or large institutional investors, investing in rounds that are both meaningful in size and old enough to count. Investments made shortly before the application, by parties connected with founders, or at valuations that look engineered tend to receive less weight. The Exchange's guidance letters explain how size, timing and investor type are assessed.

Worked example: testing both 18C thresholds

Consider a hypothetical pre-commercial advanced materials company that expects a valuation of HK$9 billion at IPO and plans to file in early 2027. Under the temporary rules it clears the HK$8 billion pre-commercial threshold. If the timetable slips so that its application, or a renewal, is submitted after 31 August 2027, and the original HK$10 billion threshold applies, the same valuation fails. If its specialist technology revenue reaches HK$250 million first, it becomes a commercialised company and needs only HK$4 billion, or HK$6 billion under the original rule. The board should therefore model revenue, valuation and timing together, rather than assuming the temporary regime will last.

Comparing Chapter 18A and 18C listings with other routes

Some companies qualify for more than one route, and the choice is strategic rather than technical. A medical technology company might fit Chapter 18A or, once revenue grows, the ordinary Main Board tests. A hardware company might meet Chapter 18C or the market capitalisation and revenue test. A founder-led company may want weighted voting rights under Chapter 8A. The comparison below is simplified.

The decision affects the valuation narrative, the investor base the bookrunners target, ongoing disclosure and stock markers, and whether a later dual listing remains straightforward. Companies should also compare the cost and timing of meeting the sophisticated investor requirements against waiting a year for revenue to mature. For the wider IPO picture, including US listings, see A-share, Hong Kong and US IPOs.

Timeline for Chapter 18A and 18C listings

Every project differs, but the steps below show the usual order of work. Many applicants for Chapter 18A and 18C listings spend longer on the pre-IPO phase than on the formal application.

1. Eligibility assessment (12 to 24 months before listing): test the business against the 18A or 18C criteria; for 18C, confirm the industry fit or prepare a pre-IPO enquiry; model market capitalisation under both temporary and original thresholds.
2. Pre-IPO rounds: bring in sophisticated independent investors early enough, and in large enough amounts, to count; document independence; restructure the group if an offshore holding company is needed.
3. Restructuring and Mainland compliance: clean up the shareholding, employee incentive plans, data and technology licensing; consider foreign investment restrictions and any VIE arrangements.
4. TECH engagement and filing: pre-filing discussions with the Exchange; confidential submission of the application proof; CSRC filing within three working days after the Hong Kong application.
5. Review and hearing: respond to Exchange and SFC comments and to CSRC questions; finalise cornerstone and pathfinder arrangements.
6. Bookbuild and listing: marketing, price-setting and allocation to independent institutional investors; post-listing lock-ups begin.

The Technology Enterprises Channel and confidential filing

On 6 May 2025 the SFC and HKEX launched the Technology Enterprises Channel (TECH). It gives prospective Chapter 18A and 18C applicants access to a specialised team for pre-filing engagement on eligibility, suitability and case-specific issues. Applicants under both chapters may also submit their application proofs confidentially, so that a listing plan and sensitive technology details are not exposed before the company is ready.

The Exchange also updated its guidance so that companies fully meeting Chapter 18A or 18C are presumed to satisfy the innovative company and external validation requirements for weighted voting rights under Chapter 8A, while the other Chapter 8A conditions still apply. Details are in the joint announcement.

Mainland and cross-border issues for applicants

Most applicants under these chapters have their main operations in Mainland China, so the CSRC overseas filing regime applies, with the filing due within three working days after the Hong Kong application is submitted. Biotech companies need to consider human genetic resources rules, clinical trial data and export controls on certain technologies. Specialist technology companies may face questions on cybersecurity review, data export, export control classification and foreign investment restrictions.

Investor-side rules matter as much as issuer-side ones. US investors should check whether the US outbound investment rules, which have applied since 2 January 2025 to certain semiconductor, quantum and artificial intelligence activities, affect a pre-IPO round or a cornerstone subscription; see US-China cross-border issues. European and ASEAN investors should review sanctions screening and any internal policies on sensitive technology. Semiconductor and AI applicants should expect bookrunners to ask about export control exposure, covered under semiconductors and critical technologies.

Holding structure and filing scope

Many applicants list through an offshore holding company, sometimes with contractual arrangements over Mainland operating entities where foreign ownership is restricted. The CSRC filing for Chapter 18A and 18C listings covers both direct H-share listings and these indirect structures, and the filing report must explain the structure, its compliance and any foreign investment restrictions. Employee incentive plans, pre-IPO convertible instruments and overseas investment registrations by Mainland-resident founders all need to be in order before filing. Structuring issues are covered under red-chip and VIE structures.

Prospectus liability is a further cross-border point. Directors of Hong Kong applicants carry statutory responsibility for the prospectus, and US-style offerings to qualified institutional buyers add disclosure standards and due diligence expectations that sponsors and underwriters will insist on for Chapter 18A and 18C listings with a Rule 144A tranche.

After listing: ongoing obligations and common mistakes

Chapter 18A and 18C companies are subject to enhanced disclosure in periodic reports on R&D progress and, for pre-commercial companies, on progress toward commercialisation. Lock-ups for cornerstone investors and controlling shareholders apply, and pathfinder investors in 18C companies face additional restrictions. A significant change of business requires Exchange consent. Follow-on fundraising is common and is discussed under H-share placements and follow-on offerings.

The "B" and "P" markers are not permanent. A Chapter 18A company that meets an ordinary financial eligibility test, or a pre-commercial 18C company that reaches the commercialisation revenue threshold, can apply to remove its marker, and with it some of the additional disclosure. Until then, disclosure of cash runway, pipeline setbacks and commercialisation progress is closely read by investors and the Exchange alike.

Companies that later seek a second listing on a Mainland exchange, or an A+H structure, should keep their governance, accounting and disclosure practices compatible with Mainland expectations from the outset. Hong Kong-listed groups considering Southbound inclusion should also review Hong Kong-Mainland market connectivity, because inclusion can change their investor base.

Common mistakes we see in planning Chapter 18A and 18C listings include:

• bringing in sophisticated investors too late, or in amounts too small, to count towards validation;
• overlooking connections between "independent" investors and founders or controlling shareholders;
• modelling only the temporary 18C thresholds when the application or a renewal may slip beyond August 2027;
• treating the CSRC filing as an afterthought rather than a parallel workstream; and
• underestimating the disclosure burden of R&D milestones once listed.

How TRW & Co helps

We advise biotech and technology companies, their founders and investors on whether Chapter 18A and 18C listings fit their plans, and on structuring the pre-IPO rounds that provide sophisticated investor validation. We work on Hong Kong law matters within our lawyers' qualifications, prepare and negotiate investment, cornerstone and underwriting documents, and plan the interaction between the Hong Kong timetable, the CSRC filing and other Chinese regulatory steps. For PRC legal opinions and Mainland filings we work with licensed PRC law firms and coordinate their input with the sponsor and Hong Kong counsel. For an initial assessment, please contact us.